Exagen (XGN) Free Cash Flow (2018 - 2026)

Exagen (XGN) has 9 years of Free Cash Flow data on file, last reported at -$10.5 million in Q1 2026.

• Quarterly Free Cash Flow rose 3.3% year-over-year to -$10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.5 million (up 16.93% YoY) and the FY2025 annual result came in at -$12.8 million, up 2.9% from the prior year.
• Free Cash Flow retreated to -$10.5 million in Q1 2026, from -$2.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $8.4 million in Q4 2023 to a low of -$10.8 million in Q1 2025.
• A 5-year average of -$5.1 million and a median of -$7.1 million in 2022 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 229.65% in 2025, down 377.23% in 2025.
• Tracing XGN's Free Cash Flow over 5 years: stood at -$9.4 million in 2022, then surged by 188.91% to $8.4 million in 2023, then plunged by 90.49% to $795000.0 in 2024, then tumbled by 377.23% to -$2.2 million in 2025, then tumbled by 375.91% to -$10.5 million in 2026.
• The last three Free Cash Flow figures came in at -$10.5 million (Q1 2026), -$2.2 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.